Financhill
Back

Revance Therapeutics Stock Predictions

Revance Therapeutics Stock Forecast

  • Is Revance Therapeutics Stock Undervalued?
    The current Revance Therapeutics [RVNC] share price is $3.08. The Score for RVNC is 17, which is 66% below its historic median score of 50, and infers higher risk than normal.
  • RVNC is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Revance Therapeutics Stock Go Up Next Year?

Data Unavailable

Revance Therapeutics Stock Rating

Data Unavailable

Revance Therapeutics Stock Price History

Is RVNC stock going to rise?

  • The current trend is relatively stagnant and RVNC is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Pharmaceuticals
Sector:
Health Care
Type:
stock
Website:
revance.com

52-Week Data

52-Week High:
9.75
52-Week Low:
2.30

Prediction Charts

Market Cap:
323.1M
Price in USD:
3.08
Volume:
407.6K
Beta:
0.92

Technical Analysis

SMA50:
4.28
SMA100:
5.00
SMA200:
4.34
52-Wk Change:
-64.06%

Stock Predictions

  • Is Revance Therapeutics stock public?
    Yes, Revance Therapeutics is a publicly traded company.
  • What is the Revance Therapeutics stock quote today?
    The Revance Therapeutics stock price is 3.08 USD today.
  • How to buy Revance Therapeutics stock online?
    You can buy Revance Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Dec-5 4.06 3.94 4.14 3.74
Dec-6 3.88 3.82 3.95 3.77
Dec-9 3.04 3.03 3.05 3.01
Dec-10 3.03 3.03 3.03 3.02
Dec-11 3.02 3.04 3.04 3.02
Dec-12 3.09 3.09 3.10 3.07
Dec-13 3.08 3.08 3.11 3.08
Dec-16 3.08 3.09 3.09 3.08
Dec-17 3.08 3.07 3.09 3.06
Dec-18 3.08 3.08 3.08 3.07
Dec-19 3.09 3.07 3.09 3.07
Dec-20 3.07 3.08 3.09 3.07
Dec-23 3.07 3.07 3.09 3.06
Dec-24 3.07 3.08 3.08 3.07

Revance Therapeutics Earnings

Data Unavailable

Revance Therapeutics Forecast Revenue Growth

Data Unavailable

  • Analysts estimate an earnings increase this quarter of $0.31 per share, a decrease next quarter of $0.00 per share, an increase this year of $2.38 per share, and an increase next year of $0.63 per share.

* Revance Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.